Medytox Receives Domestic Approval for 100 Units of Liquid Botulinum 'Innotox'

[Asia Economy Reporter Cho Hyun-ui] Medytox announced on the 2nd that its world’s first liquid-type botulinum toxin type A formulation, Innotox Injection 100 units, developed using its own technology, has obtained domestic marketing approval.

With this approval, Medytox has secured a lineup of various dosages alongside the existing Innotox 25 units and 50 units. The operation rate of the second plant, dedicated to Innotox and compliant with the US Current Good Manufacturing Practice (cGMP), will also increase.

Innotox, developed in 2014 as the world’s first, is a botulinum toxin formulation that enhances safety by completely excluding human serum albumin and animal-derived substances in the manufacturing process. Developed in a liquid form, it can be used immediately without a separate dilution process. This improves procedural convenience and allows for more precise dosage calculation.

Jung Hyun-ho, CEO of Medytox, said, "By securing a lineup of various dosages, we can target the market according to consumer demand. Clinical trials for additional indications of Innotox are actively underway, which will further accelerate our lead in the premium toxin market."

Meanwhile, to advance Innotox into developed markets, Medytox signed a technology transfer agreement with Allergan in the US in 2013. Allergan is currently conducting Phase 3 clinical trials in the US and Europe, aiming to launch Innotox in the US by 2022.

This content was produced with the assistance of AI translation services.